Close Menu

NEW YORK – Myriad Genetics announced on Wednesday morning that it is withdrawing its fiscal year 2020 financial guidance due to the impact of the COVID-19 pandemic.

Before mid-March, Myriad was experiencing test volume trends in line with its expectations, but starting late March and into its fiscal fourth quarter, social distancing guidelines began significantly impacting test volume trends, according to Bryan Riggsbee, the company's interim CEO and CFO. He didn't provide any further details on the magnitude of the impact.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.